Grafting of iPS cell-derived tenocytes promotes motor function recovery after Achilles tendon rupture.
Taiki NakajimaAkihiro NakahataNaoki YamadaKeiko YoshizawaTomoaki M KatoMio IwasakiChengzhu ZhaoHiroshi KurokiMakoto IkeyaPublished in: Nature communications (2021)
Tendon self-renewal is a rare occurrence because of the poor vascularization of this tissue; therefore, reconstructive surgery using autologous tendon is often performed in severe injury cases. However, the post-surgery re-injury rate is relatively high, and the collection of autologous tendons leads to muscle weakness, resulting in prolonged rehabilitation. Here, we introduce an induced pluripotent stem cell (iPSC)-based technology to develop a therapeutic option for tendon injury. First, we derived tenocytes from human iPSCs by recapitulating the normal progression of step-wise narrowing fate decisions in vertebrate embryos. We used single-cell RNA sequencing to analyze the developmental trajectory of iPSC-derived tenocytes. We demonstrated that iPSC-tenocyte grafting contributed to motor function recovery after Achilles tendon injury in rats via engraftment and paracrine effects. The biomechanical strength of regenerated tendons was comparable to that of healthy tendons. We suggest that iPSC-tenocytes will provide a therapeutic option for tendon injury.
Keyphrases
- induced pluripotent stem cells
- single cell
- stem cells
- minimally invasive
- anterior cruciate ligament reconstruction
- rotator cuff
- bone marrow
- coronary artery bypass
- endothelial cells
- cell therapy
- rna seq
- skeletal muscle
- risk assessment
- high glucose
- drug induced
- high throughput
- platelet rich plasma
- coronary artery disease
- myasthenia gravis